These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 37073636)

  • 1. Multicentre case-control study evaluating the safety of anti-SARS-CoV-2 vaccines in a cohort of patients with systemic vasculitis.
    Simoncelli E; Conticini E; Colafrancesco S; Gattamelata A; Spinelli FR; Garufi C; Truglia S; Grazzini S; Giardina F; Izzo R; Cantarini L; Frediani B; Conti F; Priori R
    Clin Exp Rheumatol; 2023 Apr; 41(4):922-927. PubMed ID: 37073636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity.
    Chighizola CB; Suardi I; Carrea G; Argolini L; Gattinara M; Marino A; Pontikaki I; Caporali R; Gerosa M
    Rheumatology (Oxford); 2023 Sep; 62(9):3146-3150. PubMed ID: 36702464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccination rate and safety profile in a multicentre Italian population affected by mixed cryoglobulinaemic vasculitis.
    Vacchi C; Testoni S; Visentini M; Zani R; Lauletta G; Gragnani L; Filippini D; Mazzaro C; Fraticelli P; Quartuccio L; Padoan R; Castelnovo L; Zignego AL; Ferri C; Scarpato S; Casato M; Hoxha A; Salvarani C; Monti G; Galli M; Sebastiani M
    Clin Exp Rheumatol; 2023 Apr; 41(4):787-791. PubMed ID: 35894064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
    Heshin-Bekenstein M; Ziv A; Toplak N; Hagin D; Kadishevich D; Butbul YA; Saiag E; Kaufman A; Shefer G; Sharon O; Pel S; Elkayam O; Uziel Y
    Rheumatology (Oxford); 2022 Nov; 61(11):4263-4272. PubMed ID: 35179569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
    Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
    Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
    Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
    Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
    Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
    Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey.
    Rider LG; Parks CG; Wilkerson J; Schiffenbauer AI; Kwok RK; Noroozi Farhadi P; Nazir S; Ritter R; Sirotich E; Kennedy K; Larche MJ; Levine M; Sattui SE; Liew JW; Harrison CO; Moni TT; Miller AK; Putman M; Hausmann J; Simard JF; Sparks JA; Miller FW;
    Rheumatology (Oxford); 2022 Jun; 61(SI2):SI143-SI150. PubMed ID: 35460240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndrome.
    Verstappen GM; de Wolff L; Arends S; Heiermann HM; van Sleen Y; Visser A; Terpstra JH; Diavatopoulos DA; van der Heiden M; Vissink A; van Baarle D; Kroese FGM; Bootsma H
    RMD Open; 2022 Apr; 8(1):. PubMed ID: 35414631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review.
    Xie Y; Liu Y; Liu Y
    Front Immunol; 2022; 13():919979. PubMed ID: 35860285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 vaccination-induced cutaneous vasculitis: Report of two new cases and literature review.
    Abdelmaksoud A; Wollina U; Temiz SA; Hasan A
    Dermatol Ther; 2022 Jun; 35(6):e15458. PubMed ID: 35306713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares.
    Carubbi F; Alunno A; Santilli J; Natali L; Mancini B; Di Gregorio N; Del Pinto R; Viscido A; Grassi D; Ferri C
    RMD Open; 2022 Sep; 8(2):. PubMed ID: 36282905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey.
    Ellul P; Revés J; Abreu B; Chaparro M; Gisbert JP; Allocca M; Fiorino G; Barberio B; Zingone F; Pisani A; Cassar D; Michalopoulos G; Mantzaris G; Koutroubakis I; Karmiris K; Katsanos K; Ďuricova D; Burisch J; Madsen GR; Maaser C; Naila A; Orfanoudaki E; Milivojevic V; Buisson A; Avedano L; Leone S; Torres J
    J Crohns Colitis; 2022 Aug; 16(7):1070-1078. PubMed ID: 35037033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome.
    Inanc N; Kostov B; Priori R; Flores-Chavez A; Carubbi F; Szántó A; Valim V; Bootsma H; Praprotnik S; Fernandes Moça Trevisani V; Hernández-Molina G; Hofauer B; Pasoto SG; López-Dupla M; Bartoloni E; Rischmueller M; Devauchelle-Pensec V; Abacar K; Giardina F; Alunno A; Fanny Horváth I; de Wolff L; Caldas L; Retamozo S; Ramos-Casals M; Brito-Zerón P;
    Clin Exp Rheumatol; 2022 Dec; 40(12):2290-2297. PubMed ID: 36441656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus.
    Yoshida T; Tsuji H; Onishi A; Takase Y; Shirakashi M; Onizawa H; Hiwa R; Kitagori K; Akizuki S; Nakashima R; Tanaka M; Yoshifuji H; Morinobu A
    Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35961691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New-onset systemic vasculitis following SARS-CoV-2 infection and vaccination: the trigger, phenotype, and outcome.
    Mv P; Auanassova A; Yessirkepov M; Zimba O; Gasparyan AY; Kitas GD; Ahmed S
    Clin Rheumatol; 2023 Oct; 42(10):2761-2775. PubMed ID: 37422611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases.
    Yeo JG; Chia WN; Teh KL; Book YX; Hoh SF; Gao X; Das L; Zhang J; Sutamam N; Lim AJM; Poh SL; Tay SH; Nay Yaung K; Ong XM; Hazirah SN; Chua CJH; Leong JY; Wang LF; Albani S; Arkachaisri T
    Rheumatology (Oxford); 2022 Nov; 61(11):4472-4481. PubMed ID: 35199166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of COVID-19 vaccines and disease flares after vaccines in children with rheumatic disease.
    Arslanoglu Aydin E; Baglan E; Bagrul I; Tuncez S; Ozdel S; Bulbul M
    Postgrad Med; 2022 Aug; 134(6):616-621. PubMed ID: 35535525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.